There is no generic version of Wegovy available in the United States. The active ingredient, semaglutide, is protected by patents that don’t expire until 2032 in the U.S., and no generic manufacturer has received FDA approval to sell a substitute. That leaves people paying full price unless they qualify for insurance coverage or a manufacturer discount.
Why No Generic Exists Yet
Novo Nordisk, the company that makes Wegovy, holds U.S. patents on semaglutide that extend through 2032. Until those patents expire or are successfully challenged, no other company can legally sell a generic version in the United States. Patents in other countries expire sooner, which is why generic development is further along outside the U.S. In Canada, for example, at least five generic manufacturers have filed applications with regulators, including Sandoz, Apotex, and Hikma Pharmaceuticals. Sandoz has said it would price its generic at up to 70% below the branded version, which could bring monthly costs from roughly $1,000 CAD down to $300 or less.
None of that helps U.S. consumers right now. Even if a generic enters the Canadian market first, importing prescription drugs from Canada for personal use remains legally complicated and largely unenforced rather than clearly permitted.
Compounded Semaglutide Is Not the Same Thing
You may have seen compounding pharmacies advertising semaglutide at lower prices. These are not generics. Compounded drugs are mixed by specialty pharmacies, typically from bulk ingredients, and they don’t go through the same approval process the FDA requires for branded or generic medications.
The FDA has raised specific safety concerns about compounded semaglutide. Some compounders use salt forms of the drug, such as semaglutide sodium or semaglutide acetate, which are chemically different active ingredients from what’s in Wegovy. The FDA has stated it does not have information on whether these salt forms share the same properties as the approved drug, and it is not aware of any lawful basis for using them in compounding.
Compounding semaglutide was more common during the drug shortage, when pharmacies were allowed to fill the gap. As of early 2026, semaglutide no longer appears on the FDA’s drug shortage list, which significantly restricts compounders’ legal ability to produce it. Under federal law, compounders generally cannot make drugs that are “essentially copies” of commercially available products once the shortage ends.
What Wegovy Costs Right Now
Novo Nordisk introduced a subscription pricing model for injectable Wegovy. Monthly costs range from $329 on a three-month plan to $249 on a twelve-month plan. These prices apply through the manufacturer’s direct channels and represent a significant drop from the previous list price, which ran over $1,300 per month.
The company also offers a savings card that can bring the copay down to $25 per month, but eligibility is limited. You need a valid prescription, commercial insurance that covers Wegovy, and you cannot be enrolled in Medicare, Medicaid, or other government healthcare programs. If you don’t have commercial coverage, the savings card won’t apply.
Ozempic Contains the Same Ingredient
Ozempic and Wegovy both contain semaglutide, but they’re approved for different purposes. Ozempic is indicated for type 2 diabetes, while Wegovy is approved for weight management. Wegovy’s top maintenance dose (2.4 mg weekly) is higher than what’s typically prescribed with Ozempic. Neither drug is available in generic form.
Some doctors prescribe Ozempic off-label for weight loss, and because it’s been on the market longer, insurance coverage can sometimes be easier to obtain through a diabetes-related indication. Switching between the two involves adjusting doses and should be managed by a prescriber, since the pen designs and dose strengths differ.
Alternatives With Different Active Ingredients
If cost is the main barrier, a different branded medication may be worth discussing with your doctor. Zepbound, made by Eli Lilly, uses a different active ingredient (tirzepatide) that works on two gut hormone pathways instead of one. In a head-to-head trial published in The New England Journal of Medicine, Zepbound produced an average weight loss of 20.2% over 72 weeks compared to 13.7% with Wegovy. Nearly half of people on Zepbound lost 20% or more of their body weight, versus about 27% on Wegovy.
Zepbound isn’t cheaper at list price, but Eli Lilly has run its own savings programs and direct-to-consumer pricing that can undercut what some patients pay for Wegovy. Insurance formularies also vary, so one drug may be covered where the other isn’t. Checking with your insurer before committing to either is the most practical first step.
What to Expect in the Coming Years
The 2032 patent expiration is the key date for a true generic semaglutide in the U.S. Generic manufacturers could potentially enter the market before then if they successfully challenge Novo Nordisk’s patents in court, as sometimes happens with blockbuster drugs, but no such challenge has resulted in early U.S. entry so far. Until then, the options are brand-name Wegovy, brand-name alternatives like Zepbound, or working with your insurer and the manufacturer’s savings programs to reduce out-of-pocket costs.